Director, US Analytics, Lung

8+ years of experience in pharmaceutical, biotechnology, healthcare analytics, or management consulting.

Oncology analytics experience required; lung cancer experience strongly preferred.

Demonstrated expertise working with healthcare claims, EMR, specialty pharmacy, and other patient-level datasets.

Experience supporting oncology product launches and pre-launch planning.

Proven ability to influence cross-functional teams and senior leadership.

Deep understanding of NSCLC and biomarker-driven oncology markets.

Reporting to the Executive Director, Lung Analytics & Insights, the Director, Lung Analytics will serve as the analytics lead for Revolution Medicines’ lung cancer portfolio.

This role will partner closely with Commercial, Medical Affairs, Market Access, Clinical Development, and Business Operations to generate actionable insights that inform portfolio strategy, launch readiness, commercialization planning, and business performance.

The role requires a strong understanding of the lung cancer treatment landscape, patient journey, biomarker-driven markets, and oncology data assets.

Lead analytics strategy and execution for Revolution Medicines’ lung cancer portfolio.

Partner with cross-functional stakeholders to identify key business questions and translate them into analytical plans and actionable recommendations.

Generate insights from patient-, physician-, claims-, EMR-, and market-level data to inform portfolio strategy, launch planning, and commercial decision-making.